1hon MSN
Machine learning and cell imaging combine to predict effectiveness of multiple sclerosis medication
Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will respond to natalizumab, one of the most commonly used drugs for treating ...
People with MS experience significant changes in cognition more than a year before significant physical decline is evident, a ...
The MIND diet significantly reduces disability and fatigue, improving quality of life for people with MS, a long-term study ...
21hon MSN
Menopause linked to distinct differences in multiple sclerosis presentation and comorbidities
New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis ...
Major revisions to the diagnostic criteria for neuromyelitis optica spectrum disorder will broaden their scope to related syndromes and have a substantial clinical impact.
News-Medical.Net on MSN
Consumption of ultra-processed foods may exacerbate disease activity in early multiple sclerosis
Higher intake of ultra-processed foods (UPFs) may exacerbate disease activity in early multiple sclerosis (MS), according to ...
News-Medical.Net on MSN
Menopause Found to shape initial symptoms and comorbidities in multiple sclerosis
New research presented today at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis ...
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple SclerosisAcross non-active progressive MS (primary progressive and secondary ...
Elevated vitamin D levels may lower the risk for MS in White individuals, though this association is less pronounced in Black individuals.
KGUN Tucson, AZ on MSN
U of A study finds existing drug may speed bone healing process
Researchers say a drug already used to help people with multiple sclerosis walk better could speed up how bones repair themselves.
Merck KGaA's chief executive Belén Garijo will end her time at the helm of the company next April, five years after taking ...
MedPage Today on MSN
Ulcerative Colitis: Next Target for CAR T-Cell Therapy?
The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results